HEALWELL and WELL Health Announce Competition Bureau has Concluded Its Merger Review and Issued a No Action Letter

(TSX:AIDX) HEALWELL AI Inc. and (TSX:WELL) WELL Health Technologies Corp. announced that the Commissioner of Competition has concluded the Competition Bureau's review of WELL's acquisition of a majority interest in HEALWELL and has issued a No Action Letter. The No Action Letter was issued on October 22, 2026, confirming that the Commissioner does not, at this time, intend to make an application under section 92 of the Competition Act regarding WELL's acquisition of a controlling interest in HEALWELL, which was completed on April 1, 2025, including HEALWELL's concurrent acquisition of Orion Health. In December 2025, the Bureau announced that it had obtained a Federal Court order for the production of records and information relating to the Transaction. HEALWELL and WELL cooperated with the Bureau throughout its review and produced the records and information requested. Hamed Shahbazi, Chairman of HEALWELL, stated that the company is pleased with the conclusion of the review and the issuance of the No Action Letter, and that HEALWELL remains focused on executing its strategy and delivering value to healthcare practitioners, patients, and shareholders. James Lee is the Chief Executive Officer of HEALWELL AI Inc. HEALWELL AI is a healthcare artificial intelligence company focused on preventative care, developing and acquiring technology and clinical science capabilities, including data science, AI-powered patient identification, and clinical decision support. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". WELL Health Technologies Corp. is Canada's largest outpatient healthcare company and a leading provider of technology-enabled healthcare solutions. WELL owns and operates 275 clinics in Canada, supporting more than 5 million annual patient visits. WELL provides electronic medical records, AI-powered clinical tools, patient engagement platforms, IT management services, and cybersecurity services through its subsidiaries WELLSTAR and CYBERWELL. WELL is publicly traded on the TSX under the symbol "WELL" and on the OTC Exchange under the symbol "WHTCF".

HEALWELL AI Named to TIME's World's Top HealthTech Companies of 2026 and Announces 12 Real-World Evidence and Clinical AI Presentations at International Conferences This Fall.

(TSX:AIDX) HEALWELL AI Inc. (OTCQX:HWAIF), a healthcare artificial intelligence company focused on preventative care, announced it has been named to TIME's list of the World's Top HealthTech Companies of 2026. The company, together with its life sciences and clinical collaborators, is presenting 12 scientific abstracts and presentations at 8 international conferences in fall 2026, with 9 presentations still to come through November. The research program includes real-world evidence (RWE) studies generated from DARWEN™ AI-enabled real-world data developed with life sciences partners across 5 therapeutic areas, as well as HEALWELL-led research on clinical AI design, implementation, evaluation, and governance. The TIME ranking was developed in partnership with Statista, evaluating thousands of health technology companies across three dimensions: financial performance (50% of the total score), reputation analysis (30%), and online engagement (20%), with the 500 highest-scoring companies recognized across 6 market segments. HEALWELL was included in the AI & Data Analytics category. Aaron Leibtag, Head of Global Health Systems AI Strategy at HEALWELL and Co-founder of Pentavere Research Group Inc. (now HEALWELL DARWEN Inc.), commented on the significance of the recognition and the scientific foundation of the platform. Dr. Christopher Pettengell, Chief Medical Officer of HEALWELL, highlighted the ability of the DARWEN™ AI platform to turn unstructured clinical information into real-world evidence across a range of conditions, and noted an oral presentation at the Canadian Cardiovascular Congress. James Lee, Chief Executive Officer of HEALWELL, stated that the company has more than 30 master service agreements with pharmaceutical companies, including 8 of the world's top 10, and that DARWEN™ has 57+ peer-reviewed publications. The fall 2026 conference presentations include topics in dermatology, gastroenterology, cardiology, oncology, and women's health, with presentations at EADV Congress (Vienna), ACG Annual Scientific Meeting (Nashville), Canadian Cardiovascular Congress (Ottawa), The Menopause Society Annual Meeting (San Diego), AI-MEDX (Marrakech), AMIA Annual Symposium (Dallas), ISPOR Europe (Vienna), and HealthAI Global Governance Forum (London). In 2026, HEALWELL and Pentavere research has had 20 abstracts and manuscripts accepted or published across 12 scientific congresses and 4 peer-reviewed journals, developed in collaboration with 9 life sciences partners and 2 healthcare institutions, alongside 4 HEALWELL-led studies. Manuscripts published or accepted for publication in 2026 include work in Clinical Nutrition ESPEN, the Journal of the Canadian Association of Gastroenterology, Clinical and Translational Radiation Oncology, and the Canadian Journal of Cardiology Open.

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

(NASDAQ:AIDX) 20/20 BioLabs, Inc. announced that it has entered into a standstill agreement with Streeterville Capital, LLC relating to the Company’s outstanding Series E Convertible Preferred Stock. The Agreement became effective on July 16, 2026, and restricts Streeterville from converting any shares of Series E Preferred Stock into common stock for a 120-day period unless the common stock trades at a price at least 10% above the “Minimum Price” as defined under Nasdaq Rule 5635. The Standstill will terminate immediately upon any breach of the Agreement or any Event of Default as defined in the Certificate of Designation for the Series E Preferred Stock. Upon expiration or termination of the Standstill, Streeterville may resume converting shares of the Series E Preferred Stock in accordance with the terms of the applicable transaction documents. The Series E Preferred Stock and all related transaction documents remain in full force and effect except as expressly provided in the Agreement. Additional information regarding the Agreement will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission. 20/20 BioLabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.